LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | Dasatinib | 1.11 | uM | LJP6 | 3 | I03 | 72 | hr | 1097 | 991 | 3696 | 0.2681 | -0.0565 |
BT-20 | Dasatinib | 1.11 | uM | LJP5 | 1 | D03 | 72 | hr | 1097 | 1253 | 3735 | 0.3355 | 0.0780 |
BT-20 | Dasatinib | 1.11 | uM | LJP5 | 2 | D03 | 72 | hr | 1097 | 1475 | 3877 | 0.3804 | 0.1764 |
BT-20 | Dasatinib | 1.11 | uM | LJP5 | 3 | D03 | 72 | hr | 1097 | 1471 | 3925 | 0.3747 | 0.1728 |
BT-20 | Dasatinib | 3.33 | uM | LJP6 | 1 | I02 | 72 | hr | 1097 | 1039 | 3610 | 0.2878 | -0.0312 |
BT-20 | Dasatinib | 3.33 | uM | LJP6 | 2 | I02 | 72 | hr | 1097 | 970 | 3713 | 0.2612 | -0.0677 |
BT-20 | Dasatinib | 3.33 | uM | LJP6 | 3 | I02 | 72 | hr | 1097 | 948 | 3696 | 0.2565 | -0.0801 |
BT-20 | Dasatinib | 3.33 | uM | LJP5 | 1 | D02 | 72 | hr | 1097 | 1048 | 3735 | 0.2806 | -0.0257 |
BT-20 | Dasatinib | 3.33 | uM | LJP5 | 2 | D02 | 72 | hr | 1097 | 1326 | 3877 | 0.3420 | 0.1096 |
BT-20 | Dasatinib | 3.33 | uM | LJP5 | 3 | D02 | 72 | hr | 1097 | 1218 | 3925 | 0.3103 | 0.0584 |
BT-20 | Dasatinib | 10 | uM | LJP6 | 1 | I01 | 72 | hr | 1097 | 840 | 3610 | 0.2327 | -0.1440 |
BT-20 | Dasatinib | 10 | uM | LJP6 | 2 | I01 | 72 | hr | 1097 | 787 | 3713 | 0.2119 | -0.1722 |
BT-20 | Dasatinib | 10 | uM | LJP6 | 3 | I01 | 72 | hr | 1097 | 744 | 3696 | 0.2013 | -0.1989 |
BT-20 | Dasatinib | 10 | uM | LJP5 | 1 | D01 | 72 | hr | 1097 | 874 | 3735 | 0.2340 | -0.1208 |
BT-20 | Dasatinib | 10 | uM | LJP5 | 2 | D01 | 72 | hr | 1097 | 1262 | 3877 | 0.3254 | 0.0798 |
BT-20 | Dasatinib | 10 | uM | LJP5 | 3 | D01 | 72 | hr | 1097 | 1159 | 3925 | 0.2953 | 0.0302 |
BT-20 | Tozasertib | 0.04 | uM | LJP5 | 1 | B18 | 72 | hr | 1097 | 1813 | 3735 | 0.4854 | 0.3286 |
BT-20 | Tozasertib | 0.04 | uM | LJP5 | 2 | B18 | 72 | hr | 1097 | 1992 | 3877 | 0.5137 | 0.3874 |
BT-20 | Tozasertib | 0.04 | uM | LJP5 | 3 | B18 | 72 | hr | 1097 | 2278 | 3925 | 0.5803 | 0.4877 |
BT-20 | Tozasertib | 0.12 | uM | LJP5 | 1 | B17 | 72 | hr | 1097 | 1303 | 3735 | 0.3488 | 0.1021 |
BT-20 | Tozasertib | 0.12 | uM | LJP5 | 2 | B17 | 72 | hr | 1097 | 1374 | 3877 | 0.3543 | 0.1314 |
BT-20 | Tozasertib | 0.12 | uM | LJP5 | 3 | B17 | 72 | hr | 1097 | 1492 | 3925 | 0.3801 | 0.1819 |
BT-20 | Tozasertib | 0.37 | uM | LJP5 | 1 | B16 | 72 | hr | 1097 | 1193 | 3735 | 0.3194 | 0.0485 |
BT-20 | Tozasertib | 0.37 | uM | LJP5 | 2 | B16 | 72 | hr | 1097 | 1172 | 3877 | 0.3022 | 0.0368 |
BT-20 | Tozasertib | 0.37 | uM | LJP5 | 3 | B16 | 72 | hr | 1097 | 1223 | 3925 | 0.3116 | 0.0608 |